About Ivan Bergstein
Form D filings for Lirum Therapeutics in 2023 list Ivan Bergstein as director.
Ivan Bergstein reports to the SEC as a director, officer or major shareholder of 1 public company: Stemline Therapeutics (STML).
Ivan Bergstein first appears on SEC filings in 2013.
Experience
This experience comes from SEC filings. The years are when the filings name Ivan Bergstein in the role, so the role may have started earlier or lasted longer.
SI
Stemline Therapeutics Inc.
Chief Executive Officer and director
2013 – 2020 · Public company (STML)
Key Colleagues at Startups
The people Ivan Bergstein works with at each company, as listed on that company's latest Form D.
Lirum Therapeutics, Inc. · Form D, Feb 23, 2023